Seeking Alpha

AcelRx Pharma up more than 8% in early trading

  • AcelRx Pharmaceuticals (ACRX +8.9%) enjoys investor enthusiasm today after yesterday's earnings report after the close.
  • Consensus estimate for 2014 revenue is $3.6M, but the company expects to earn a $5M milestone fee in Q3 from Grunenthal GmbH when it submits its marketing application to European regulators for Zalviso by mid-year.
  • Quick assets on hand are sufficient to fund operations through 2015.
  • Mutual fund ownership has grown from 25 to 123 over the past four quarters.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs